ClinicalTrials.gg
RecruitingNCT07169214Updated Dec 15, 2025

Evaluation of Safety, Efficacy, and Pharmacokinetics of BT-114143 Injection in Patients With Abnormal Uterine Bleeding

A Phase 1 interventional study of BT-114143 Injection at low dose and BT-114143 Injection at Medium-dose in Abnormal Uterine Bleeding, sponsored by ScinnoHub Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by ScinnoHub Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Oct 2024, registered Aug 2025).
  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

This is a randomized, double-blind, placebo-controlled, multiple-dose escalation, Phase Ib clinical study conducted in patients with abnormal uterine bleeding (e.g., AUB). It aims to evaluate the safety, efficacy, pharmacokinetic characteristics of multiple administrations of BT-114143 Injection at different doses, as well as to explore changes in coagulation-related biomarkers and quality of life.

It is planned to enroll 39 adult patients with abnormal uterine bleeding.

02

Conditions studied

  • Abnormal Uterine Bleeding

Browse trials for

03

In context

Metrorrhagia

153 studies on the registry are indexed under Metrorrhagia; 35 are open to participants now.

This study's planned enrollment of 39 is below the median of 100 across 115 interventional studies indexed under Metrorrhagia.

Browse Metrorrhagia studies →

Lead sponsor

ScinnoHub Pharmaceutical Co., Ltd. is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able to sign the form before any study-related procedures are performed, and be willing and able to comply with the study requirements;
  2. Premenopausal female subjects, aged 18-50 years, including 18 and 50 years;
  3. Have regular menstrual cycles in the past 6 months, with a menstrual cycle of ≥21 days and ≤35 days, and a menstrual period duration of ≤14 days;
  4. Meet the diagnosis of abnormal uterine bleeding and agree to be admitted for treatment. Assessed by the alkaline method, in 2 consecutive menstrual cycles during the screening period, the menstrual blood loss is >80 ml in both cycles; or the blood loss in any one cycle is ≥160 ml;
  5. The pregnancy test result is negative before randomization;
  6. Those with a [BMI = weight (kg) / height² (m²)] of 18.5-28.0 kg/m² (including the boundary values).

Exclusion criteria

Exclusion Criteria:

  1. Patients with known endometrial polyps > 1.5 cm, endometrial , or atypical hyperplasia;
  2. Patients with known or investigator-determined ovulatory dysfunctional abnormal uterine bleeding who require hormonal therapy;
  3. Patients identified by investigators as having iatrogenic abnormal uterine bleeding;
  4. Patients with abnormal uterine bleeding related to coagulation dysfunction, including but not limited to those with laboratory test results showing: count ≤ 100×10⁹/L, or prolonged by ≥ 10s beyond the , or PT prolonged by ≥ 3s beyond the upper limit of normal;
  5. Patients with bleeding caused by cervical or vaginal lesions;
  6. Patients who have undergone major surgery within 6 months prior to screening;
  7. Patients determined by investigators before randomization to require surgical treatments such as total hysterectomy, myomectomy, hysteroscopic treatment, uterine artery embolization, or ablation during the study period;
  8. Patients who have received the following medications within 3 months prior to randomization: gonadotropin-releasing hormone agonists; sex hormone drugs administered orally, by injection, vaginally, or transdermally (including but not limited to drugs containing estrogen or progesterone); selective estrogen receptor modulators; hormonal intrauterine devices (LNG-IUS). For long-acting (3-month) gonadotropin-releasing hormone agonists or progesterone preparations, the last administration must be no later than 6 months prior to randomization;
  9. Patients who have used danazol, desmopressin, tranexamic acid, aminocaproic acid, or traditional Chinese medicines for the treatment of menorrhagia within 3 months prior to randomization;
  10. Patients who need to receive anticoagulants (e.g., warfarin, heparin, etc.) or antiplatelet therapies (e.g., clopidogrel, ticagrelor, etc.) during the study period;
  11. Patients with intolerance or to BT-114143 Injection;
  12. Patients who have participated in clinical trials of other drugs, biological agents, or medical devices and received therapeutic interventions within 30 days prior to screening;
  13. Patients with clinically severe diseases such as known disorders of the circulatory, endocrine, nervous, digestive, respiratory, urinary, hematological, immunological, psychiatric, or metabolic systems, as assessed by investigators as unsuitable for participation in the trial;
  14. Patients with a known history of glaucoma or retinopathy, as assessed by investigators as unsuitable for participation in the trial;
  15. Untreated or poorly controlled thyroid dysfunction, except for mild subclinical hypothyroidism (i.e., TSH \< 10 mIU/L with normal FT4 and TT4);
  16. Patients with a known history of thrombotic diseases, including but not limited to pulmonary embolism, deep vein thrombosis, etc.;
  17. Patients diagnosed with malignant tumors within the past 5 years, except for cured basal cell carcinoma of the skin;
  18. Patients with cervical cytology results indicating a risk of cervical cancer within 1 year prior to the screening period and requiring treatment.
  19. Patients with one or more of the following abnormal laboratory test results before randomization:

    • (ALT) and/or aspartate aminotransferase (AST) > 1.5 × ULN;
    • Total > 1.5 × ULN, except for patients with Gilbert's syndrome;
    • ≤ 60 mL/min/1.73 m² (calculated using the CKD-EPI formula);
    • \< 90 g/L;
  20. Patients with known infection of (HIV), or positive surface antigen (HBsAg), or positive virus antibody (HCV Ab);
  21. Alcohol abusers (i.e., consuming more than 14 standard units of alcohol per week within 3 months before screening (1 standard unit contains 14g of alcohol, such as 360ml of beer, 45ml of spirits with 40% alcohol content, or 150ml of wine)), or those with a history of drug abuse (such as morphine, tetrahydrocannabinolic acid, methamphetamine, 3,4-methylenedioxymethamphetamine, ketamine) within 1 year before screening, or with mental or neurological diseases that investigators consider may affect participation in the study;
  22. Pregnant or lactating women, or subjects who had unprotected sex within 14 days before screening;
  23. Subjects who have plans for pregnancy from the time of signing the form until 3 months after the last administration, or subjects (or their partners) who are unwilling to take effective measures (specific contraceptive measures are shown in Appendix 1);
  24. Patients with any condition or result that investigators or designated personnel consider may pose a risk to subjects or the implementation of the study;
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    low-dose group

    Subjects received low-dose BT-114143 Injection treatment

    Drug: BT-114143 Injection at low dose

  • Experimental
    Medium-dose group

    Subjects received Medium-dose BT-114143 Injection treatment

    Drug: BT-114143 Injection at Medium-dose

  • Experimental
    High-dose Group

    Subjects received High-dose BT-114143 Injection treatment

    Drug: BT-114143 Injection at High-dose

  • Placebo comparator
    control group

    The subjects receive normal saline treatment.

    Drug: control group

Interventions

  • A total of 10 subjects were enrolled. All of them received BT-114143 Injection at low dose. BT-114143 will be administered twice daily for three consecutive days.

  • A total of 10 subjects were enrolled. All of them received BT-114143 Injection at Medium-dose. BT-114143 will be administered twice daily for three consecutive days.

  • A total of 10 subjects were enrolled. All of them received BT-114143 Injection at High-dose. BT-114143 will be administered twice daily for three consecutive days.

  • Drugcontrol group

    The ratio of subjects in the experimental group to those in the control group is 10:3, with 3 placebo - treated control subjects corresponding to each dose group. The subjects will receive placebo treatment twice a day for 3 consecutive days.

06

What researchers measure

Primary outcomes

  1. safety evaluation

    The incidence of abnormal laboratory values, clinically significant physical examination findings, vital signs, electrocardiograms (ECGs), and/or treatment-related adverse events/serious adverse events.

    Time frame: from the first administration to 2 weeks after the last administration

Secondary outcomes

  1. Change of menstrual bleeding volume from baseline

    Sanitary products used by subjects are collected regularly, and menstrual blood loss is measured by the alkaline hemoglobin method.

    Time frame: from signing the informed consent to 2 weeks after the last administration

  2. Percentage change of menstrual bleeding volume from baseline

    Sanitary products used by subjects are collected regularly, and menstrual blood loss is measured by the alkaline hemoglobin method.

    Time frame: from signing the informed consent to 2 weeks after the last administration

  3. The difference in the number of menstrual bleeding days between the post-treatment period and the baseline period in subjects.

    Time frame: From signing the informed consent to 2 weeks after the last administration

  4. The proportion of subjects with menstrual blood loss ≤ 80 ml after treatment.

    Time frame: from signing the informed consent to 2 weeks after the last administration

  5. The proportion of subjects with a reduction in menstrual blood loss of ≥50 ml after treatment compared with the baseline

    Time frame: from signing the informed consent to 2 weeks after the last administration

  6. The proportion of subjects with a reduction in menstrual blood loss of ≥36 ml after treatment compared with the baseline.

    Time frame: from signing the informed consent to 2 weeks after the last administration

  7. The change in the Menorrhagia Impact Questionnaire (MIQ) score from baseline after treatment in subjects.

    Evaluate Menorrhagia Impact Questionnaire (MIQ) score at screening visit and treatment period. The MIQ consists of six individual measures or items. The first 4 items are evaluated by using 4-point (item 1) or 5-point (items 2-4) response scales. No summative scale is derived for item 5 as it serves as a descriptive tool to characterize limitations of specific activities. Item 6 represents a global assessment (impact, degree, and meaningfulness) of the change in MBL when compared to the previous period. Scores correlate with symptom severity; a higher score indicates more severe heavy menstrual bleeding.

    Time frame: from signing the informed consent to 2 weeks after the last administration

  8. The change in the Menstrual Discomfort Questionnaire (MDQ) score from baseline after treatment in subjects.

    A total of 46 related items that reflect eight subscales were included in the MDQ. Each of the eight subscales is composed of an interrelated set of items, and each item is scored on a 5-point Likert scale. The scale ranges from 0 to 184, with higher scores indicating more severe heavy menstrual bleeding.

    Time frame: from signing the informed consent to 2 weeks after the last administration

Other outcomes

  1. To characterize the pharmacokinetic (PK) profile of BT-114143

    Plasma concentration of BT-114143 will be measured and following PK parameters will be characterized: Maximum observed concentration (Cmax); Time to Cmax (Tmax); area under the plasma concentration-time curve (AUC) from the time 0 to the last quantifiable time point (AUC0-t); AUC from the time 0 to infinity (AUC0-inf); half-life (t1/2); apparent clearance (CL/F); apparent volume of distribution (Vz/F)

    Time frame: Three days after administration

  2. Changes in Plasminogen Activity Results from Baseline

    Blood samples will be collected to determine the changes in plasminogen activation over time.

    Time frame: Three days after administration

  3. Prothrombin Time(PT)

    The change of PT from baseline

    Time frame: Three days after administration

  4. Activated Partial Thromboplastin Time(APTT)

    The change in Activated Partial Thromboplastin Time (APTT) from baseline

    Time frame: 3 days after administration

  5. International Normalized Ratio(INR)

    The change in INR (International Normalized Ratio) from baseline

    Time frame: 3 days after administration

  6. Thrombin Time(TT)

    The change in TT (Thrombin Time) from baseline

    Time frame: 3 days after administration

  7. Fibrinogen(FIB)

    The change in FIB (Fibrinogen) from baseline

    Time frame: 3 days after administration

  8. D-Dimer

    The change in D-Dimer (D-Dimer) from baseline

    Time frame: 3 days after administration

  9. Changes in Thromboelastography (TEG) Parameters

    Blood samples will be collect at each timepoints and TEG parameter (including R, K, Angle, MA, LY30, and CI values) will be measured to determine coagulation function of each subject.

    Time frame: 3 days after administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Sep 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Sep 11, 2025
StartActual
Oct 30, 2024
Primary completionActual
Sep 23, 2025
CompletionEst.
Dec 31, 2025
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07169214
Lead sponsor
ScinnoHub Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Oct 30, 2024
Primary completion
Sep 23, 2025
Completion
Dec 31, 2025 (estimated)
Last update
Dec 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BT-114143

Start the discussion